Therapeutic potential of targeting galectins – A biomaterials-focused perspective

• Published in: Biomaterials Vol. 286; p. 121585
• Main Authors: Martin-Saldaña, Sergio, Chevalier, Merari Tumin, Pandit, Abhay
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.07.2022
• Subjects: Biocompatible Materials; Biomaterial; Drug delivery; Galectin; Galectins - metabolism; Galectins - therapeutic use; Humans; Inflammation; Lectins; Polysaccharides - metabolism; Galectin; Lectins; Biomaterial; Inflammation; Drug delivery
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2022.121585

Among all the biological entities involved in the immune response, galectins, a family of glycan-binding proteins, have been described as key in immune cell homeostasis and modulation. More importantly, only some galectin family members are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. As they are expressed in most major diseases, their potential as targets for new therapies seems promising. Most of the galectin family members' ubiquitous expression points to the need for targeted treatments to ensure effectiveness. Engineered biomaterials are emerging as a promising method to improve galectin-targeted strategies' therapeutic performance. In this review, we provide an overview of the role of galectins in health and disease and their potential as therapeutic targets, as well as the state-of-the-art and future directions of galectin-targeted biomaterials.